Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

12 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRbXlxPzJiaB?= M1f4UWROW09? M17zT2lEPTB;MD6wNFAxPyEQvF2= NHvRSYsyPzl3NkC4NC=>
K562 NYDjVo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp NUC4dGcxTE2VTx?= M{S5W2lEPTB;MD6wNFEh|ryP NVnJ[np5OTd7NU[wPFA>
M07e NV\CNm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i0PVczKGh? NWjNeJBZTE2VTx?= MkL3TWM2OD1yLkCwNVIh|ryP M2n2eFE4QTV4MEiw
ALL3 MY\DfZRwfG:6aXOgRZN{[Xl? M2HsdlAvOc7:TR?= MUS3NkBp NYjjOVd2TE2VTx?= NUjNXYlJUUN3ME2wMlAxODRizszN NWfmU2ttOTl6OEm1OFA>
CML MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;uclIxKG2rbh?= NGe3c5hFVVOR Ml;CTWM2OD1yLkCwNUDPxE1? MXyxPVIyQTBzNh?=
BA/F3 NV7qNYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXNTFJIPzJiaB?= MmjTSG1UVw>? MmfzTWM2OD14LkW4PUDPxE1? MlrvNlMxQDh4NES=
BA/F3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi3NkBp NX2yeJFbTE2VTx?= NVnFXYgxUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> NGjJNoozOzB6OE[0OC=>
BA/F3 NXezTJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;pO|IhcA>? M1TTfmROW09? MUPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO MnLZNlMxQDh4NES=
BA/F3 M3vZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvZlU4PzJiaB?= M{SxR2ROW09? NYntNopOUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN NVPiWVhPOjNyOEi2OFQ>
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3NkBp M2XDbGROW09? NEjFRXhKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= NEDHSY8zOzNyMUewNy=>
BA/F3 NFm3bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp MYPEUXNQ M1vC[mlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP M124NVI{OzBzN{Cz
BA/F3 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwO|IhcA>? M1u0WmROW09? NETkWHlKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= M{nIb|I{OzBzN{Cz
BA/F3 NGPSO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTQU4Q4OiCq NEW2XYdFVVOR NXXQOpFnUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= M2PrUVI{OzBzN{Cz
BA/F3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT6O|IhcA>? M3jFS2ROW09? Mki0TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? MV6yN|MxOTdyMx?=
BA/F3 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jXcVczKGh? NW\O[ldrTE2VTx?= M36xNmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NW\ETVFpOjN|MEG3NFM>
BA/F3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HPRVczKGh? MYXEUXNQ Mk\2TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NEfoNFczOzNyMUewNy=>
BA/F3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTFO|IhcA>? MmXKSG1UVw>? M1XDZ2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO Mmf4NlM{ODF5MEO=
BA/F3 MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED0dGc4OiCq MX7EUXNQ MmHTTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NXO2WZBEOjN|MEG3NFM>
T cell M{HPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp MU\EUXNQ NF3zboJKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? MYixO|E2PDVzMh?=
WiDr MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDUO|IhcA>? MVLEUXNQ NVvvclFqUUN3ME2wMlA2OiEQvF2= Mk[2NVU3OTV3MUK=
PC3 M{nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqxSnZxPzJiaB?= M{HiR2ROW09? NHfxPJNKSzVyPUCuNFA6PCEQvF2= MmLQNVU3OTV3MUK=
MDA-MB-231 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fiNVczKGh? MUnEUXNQ NYG3ZXFzUUN3ME2wMlAyOiEQvF2= NVLCXJMyOTV4MUW1NVI>
Hs578T Mme1R5l1d3SxeHnjJGF{e2G7 Mn36O|IhcA>? NIDKXoNFVVOR MmnOS2k2OD1yLkCzJO69VQ>? NYXrW2VMOjRyMUWzNlc>
HMEC M2rW[2N6fG:2b4jpZ{BCe3OjeR?= MXy3NkBp NX;IUm8zTE2VTx?= NH3GUVhIUTVyPUGuPEDPxE1? M4nuV|I1ODF3M{K3
DU145 M3rsNGN6fG:2b4jpZ{BCe3OjeR?= NFXXNnY4OiCq NH7JcnBFVVOR NH:zeG9IUTVyPUCuNVYh|ryP MXmyOFAyPTN{Nx?=
U251 M37BXGN6fG:2b4jpZ{BCe3OjeR?= M1;MR|czKGh? NEX3Xo1FVVOR M3XIZWdKPTB;Mj64NUDPxE1? NGLOd2UzPDBzNUOyOy=>
NCI60 NFrlUXZEgXSxdH;4bYMhSXO|YYm= MV:3NkBp MmDnSG1UVw>? NXW2eVNRT0l3ME21Mlch|ryP M2\3c|I1ODF3M{K3
MALME-3M NHmzWFJEgXSxdH;4bYMhSXO|YYm= NIjXfII4OiCq MX;EUXNQ MXPHTVUxRTZwNkGg{txO MUiyOFAyPTN{Nx?=
KM12 Mkn0R5l1d3SxeHnjJGF{e2G7 MnzUO|IhcA>? M2DxOmROW09? MmHlS2k2OD15LkS0JO69VQ>? Ml\vNlQxOTV|Mke=
SW620 MXzDfZRwfG:6aXOgRZN{[Xl? MVm3NkBp M1LkWmROW09? MUDHTVUxRThwNEOg{txO MV6yOFAyPTN{Nx?=
RXF 393NL NFfsZ|hEgXSxdH;4bYMhSXO|YYm= NYX5PXJ1PCCmYYnz MWrEUXNQ NVXWOnhSUUN3ME2wMlAzOTdizszN NIP4dWwzOzJ3M{C3OC=>
LXFA 983L MlH5R5l1d3SxeHnjJGF{e2G7 MorMOEBl[Xm| M{jmTmROW09? MV\JR|UxRTBwMEW2OUDPxE1? M4K0dlI{OjV|MEe0
PRXF DU145 MUTDfZRwfG:6aXOgRZN{[Xl? NEXDWlE1KGSjeYO= MmDISG1UVw>? NXHwTpdDUUN3ME2wMlA3OjNizszN M3PQNVI{OjV|MEe0
PAXF 1657L M373XGN6fG:2b4jpZ{BCe3OjeR?= MXi0JIRigXN? MnvoSG1UVw>? NHjaT3JKSzVyPUCuNVIyKM7:TR?= M1P6dVI{OjV|MEe0
CXF 1103L NVrJUohWS3m2b4TvfIlkKEG|c3H5 NYD6UVhRPCCmYYnz M{H3bmROW09? NIrKboxKSzVyPUSuN|Yh|ryP MVuyN|I2OzB5NB?=
GXF251L MW\DfZRwfG:6aXOgRZN{[Xl? MVy0JIRigXN? MnvYSG1UVw>? NH[ydYhKSzVyPUKuNlUh|ryP MljCNlMzPTNyN{S=
NCI-H23 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3NkBp Mo[wSG1UVw>? MnPMTWM2OD1{LkK3JO69VQ>? NH;1W|EzOzV{MUCyNC=>
HCT116 NXv4RmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Ts[FczKGh? NUHXO4dYTE2VTx?= NYjPVoNMUUN3ME2yMlMh|ryP NX[zcYdmOjN3MkGwNlA>
MCF7 NY\GO5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PvcVczKGh? MUnEUXNQ NVLtO|M5UUN3ME2yMlU4KM7:TR?= M1TDWFI{PTJzMEKw
NCI-H460 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\qPFczKGh? Mk[1SG1UVw>? Ml7kTWM2OD16Lkm5JO69VQ>? MYKyN|UzOTB{MB?=
DLD1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fLVlczKGh? MXjEUXNQ NEToUW1KSzVyPUSuOkDPxE1? MlqwNlM2Pjd7NkC=
NCI-H661 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp NEO5cVdFVVOR MonvTWM2OD15Lkig{txO MVWyN|U3Pzl4MB?=
A549 M4TNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT4Tm02PzJiaB?= MkfOSG1UVw>? MlnrTWM2OD16LkKg{txO NHjNTmczOzV4N{m2NC=>
U937 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp NEnJdJZFVVOR M{\iNWlEPTB;MUKuNkDPxE1? MmXuNlM2Pjd7NkC=
HEK293 NXfze4o3TnWwY4Tpc44hSXO|YYm= MWKxNOKh|ryP NU\kZnpKTE2VTx?= Mm\wTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= NUXBTocxOjJ5N{C2NVA>
HUVEC MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjhZW4xNjF3wrFOwG0> NXvZOZkyPzJiaB?= NEPDdXdFVVOR NV7wXJZDUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO NXzFbXpJOjJ6NUO5PVM>
HUVEC MUDGeY5kfGmxbjDBd5NigQ>? MYmxOeKh|ryP NXHLT3AzPzJiaB?= M4[1dmROW09? M1v0Nmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MoPWNlI5PTN7OUO=
Plasmodium falciparum M{T3VWZ2dmO2aX;uJGF{e2G7 MnH4NVDDqM7:TR?= Mm\SNVUhdWmw NWPnZ|RiTE2VTx?= NFzFdHBKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NYrRV4F1OjR3NUCzN|A>
PC3 MmPJSpVv[3Srb36gRZN{[Xl? MVSwMlEh|ryP NVvEe4c6PSCq NYfveG1GTE2VTx?= Mnn0TY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P NWm5R3NPOTl2NkK5O|U>
DU145 MU\GeY5kfGmxbjDBd5NigQ>? NH;SOIMxNjFizszN M3e3OVUhcA>? NH24PYxFVVOR NEnFc2RKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> NWPvbpBbOTl2NkK5O|U>
PC3 MUHLbY5ie2ViQYPzZZk> MYGwMlEh|ryP M4LiR|UhcA>? MWjEUXNQ NX\wcnlyUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NFvaRmQyQTR4Mkm3OS=>
DU145 M1:3S2tqdmG|ZTDBd5NigQ>? NYPhUJNqOC5zIN88US=> NI\nc5o2KGh? Mn\ySG1UVw>? NWn6WYJUUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O MlTRNVk1PjJ7N{W=
PC3 NEPLOllMcW6jc3WgRZN{[Xl? NEfKN4wxNjFizszN MlXVOUBp M1jZSmROW09? MmPtTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O NXjqUWQ2OTl2NkK5O|U>
DU145 NXLJNFhnU2mwYYPlJGF{e2G7 MlfFNE4yKM7:TR?= M2nGWVUhcA>? NYnWNm9QTE2VTx?= M4TpeGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P MkLyNVk1PjJ7N{W=
Huh7 NU\uNYU{SW62aY\pdoFtKEG|c3H5 NX\uSmZXOi53IN88US=> NF7HR241KGSjeYO= NFXp[4xFVVOR M1v1TmlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NEPmeIIyPzN4ME[3Oi=>
C6/36 MkWyRY51cX[rcnHsJGF{e2G7 NWnydJNLOi53IN88US=> MYe0JIRigXN? NES3ZVJFVVOR MnnOTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? MVSxO|M3ODZ5Nh?=
U937 Ml\lSpVv[3Srb36gRZN{[Xl? MkDjNUDPxE1? Mo\sNUBp M1\wSGROW09? MUTS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? M1vJOlE4Pjh2MEm5
U937 NXnzNIJHTnWwY4Tpc44hSXO|YYm= NWPsZ3lJOSEQvF2= NEjhU4QyKGh? M3nDeGROW09? MVzS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> NVnSbnB5OTd4OESwPVk>
murine mast cell NULsXoNtTnWwY4Tpc44hSXO|YYm= M3P2PFEh|ryP MXuyOEBp M{T6V2ROW09? MULJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? NF7Rc4IyPzZ6NEC5PS=>
BV-173 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfqNoZKSzVyPUCuNFAxODByMUC5JO69VQ>? M4[wOnNCVkeHUh?=
K-562 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXCTI1KSzVyPUCuNFAxODByMk[2JO69VQ>? Ml7oV2FPT0WU
BL-70 NHL3c3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDTWM2OD1yLkCwNFAxODh{MjFOwG0> NHXlSpVUSU6JRWK=
EM-2 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q5UmlEPTB;MD6wNFAxODFyODFOwG0> MmjUV2FPT0WU
LAMA-84 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HuVGlEPTB;MD6wNFAxODN{MTFOwG0> NXz0bZJOW0GQR1XS
MEG-01 NVGxVpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMECwNFA6QCEQvF2= MmXNV2FPT0WU
EoL-1-cell NVXidXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUTWlEPTB;MD6wNFAxOTNzIN88US=> Ml3wV2FPT0WU
CTV-1 NITaUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjkTWM2OD1yLkCwNFA1ODRizszN Mnm4V2FPT0WU
TE-15 M3rW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEC1PFkh|ryP MoXZV2FPT0WU
NOS-1 M{HFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THOGlEPTB;MD6wNFYyOyEQvF2= NYLlVHRPW0GQR1XS
D-336MG NXjJNo11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHTmJKSzVyPUCuNFA3OyEQvF2= NE\TSY9USU6JRWK=
LB1047-RCC NGHJbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPEe2tSUUN3ME2wMlAxQTh7IN88US=> M{Ps[3NCVkeHUh?=
LB996-RCC M2nBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyTWM2OD1yLkCwPVkyKM7:TR?= M3j5T3NCVkeHUh?=
SW982 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrCVWhnUUN3ME2wMlAyOTF3IN88US=> M1THT3NCVkeHUh?=
TK10 M4LKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv2TWM2OD1yLkCxNVc1KM7:TR?= NGLkenlUSU6JRWK=
A704 M4j5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnjN5V1UUN3ME2wMlAyPDlzIN88US=> M2jxe3NCVkeHUh?=
TE-8 NYTaNlBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyTWM2OD1yLkCxOVc3KM7:TR?= MWTTRW5ITVJ?
DOHH-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H2UmlEPTB;MD6wNVcyQSEQvF2= NHf4T4xUSU6JRWK=
HOP-62 NIHLNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzvTWM2OD1yLkCxPFM1KM7:TR?= M3XiPXNCVkeHUh?=
TE-12 NWSwdIFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHRTWM2OD1yLkCxPFYyKM7:TR?= M4HSRnNCVkeHUh?=
KGN M1z0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXRVmdEUUN3ME2wMlAyQTR{IN88US=> NEOzUlhUSU6JRWK=
NCI-H1648 M2WwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF60[4hKSzVyPUCuNFIxOTFizszN MXXTRW5ITVJ?
OS-RC-2 NFX5XmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEKwN{DPxE1? NIHuRWFUSU6JRWK=
GB-1 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXtWHlKSzVyPUCuNFIyPTdizszN Mnq5V2FPT0WU
RXF393 NFv0bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\QUWlEPTB;MD6wNlM2PyEQvF2= MX;TRW5ITVJ?
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P3d2lEPTB;MD6wNlU5PiEQvF2= NXnQdZUzW0GQR1XS
KS-1 NEflT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fCZmlEPTB;MD6wNlc{KM7:TR?= MkXyV2FPT0WU
ETK-1 NHyy[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL1Ums4UUN3ME2wMlAzQDN{IN88US=> MmKxV2FPT0WU
SW954 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f6b2lEPTB;MD6wNlkzPyEQvF2= M{P3VXNCVkeHUh?=
Becker NXvEdJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P2cWlEPTB;MD6wN|AxOyEQvF2= NV;rN2hsW0GQR1XS
MZ1-PC NV;SeFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjuUW5KSzVyPUCuNFMyOTlizszN NXjMfZJZW0GQR1XS
ES6 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEOxPVMh|ryP NGKweo5USU6JRWK=
KURAMOCHI NE\U[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPXb5FKSzVyPUCuNFM1QDdizszN M{L4dXNCVkeHUh?=
CGTH-W-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEO1OFgh|ryP NWi1WVIxW0GQR1XS
VA-ES-BJ NHOwTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEO5NFIh|ryP NWnHN5BMW0GQR1XS
LXF-289 NEPHfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4OWlEPTB;MD6wN|k2PiEQvF2= MUjTRW5ITVJ?
MPP-89 M1nHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj2TWM2OD1yLkC0NFQ6KM7:TR?= MUDTRW5ITVJ?
SW872 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVriSGVEUUN3ME2wMlA1OTZzIN88US=> MUTTRW5ITVJ?
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OyTWlEPTB;MD6wOFQ{PSEQvF2= MoqzV2FPT0WU
PSN1 NHTPcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4b2NOUUN3ME2wMlA1PDd2IN88US=> NFOyPIdUSU6JRWK=
LB831-BLC NHf2d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrpdZI{UUN3ME2wMlA1PjB7IN88US=> NEXrcnNUSU6JRWK=
MFH-ino MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBPYxKSzVyPUCuNFQ4OjRizszN MV7TRW5ITVJ?
TGBC24TKB NEH5bG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfLfmxCUUN3ME2wMlA1PzZzIN88US=> NFjMT5hUSU6JRWK=
A388 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HCeWlEPTB;MD6wOVA6PSEQvF2= NYf3eFlTW0GQR1XS
BB30-HNC NIPXNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nqemlEPTB;MD6wOVQ{PyEQvF2= M4H3enNCVkeHUh?=
GI-ME-N NH7xc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnCZ2lWUUN3ME2wMlA3OTF6IN88US=> NEDzNZZUSU6JRWK=
TGBC1TKB MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXOOWJKSzVyPUCuNFYyPjRizszN M{DjOXNCVkeHUh?=
TE-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPvTWM2OD1yLkC2N|U4KM7:TR?= NFHFd2JUSU6JRWK=
A498 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PzbWlEPTB;MD6wO|I5PCEQvF2= MX;TRW5ITVJ?
TE-11 NGjpRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTZTWM2OD1yLkC3PFU5KM7:TR?= MnH4V2FPT0WU
BB65-RCC NFXURmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvZXHpKSzVyPUCuNFgzOjdizszN NI[ydG5USU6JRWK=
C2BBe1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXudoFyUUN3ME2wMlA5OzB6IN88US=> NX\qfZN[W0GQR1XS
NCI-H747 M{HueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0TWM2OD1yLkC4N|YzKM7:TR?= NFvJSG5USU6JRWK=
IST-MES1 NXfrO49vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEi1OVIh|ryP M3zZPHNCVkeHUh?=
KALS-1 NIDmVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjhcpZLUUN3ME2wMlA6PDlizszN M1\YW3NCVkeHUh?=
GCIY NHfhfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEm2OVYh|ryP Mny4V2FPT0WU
RL95-2 M3nnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3We4tKSzVyPUCuNVA{QCEQvF2= MnvOV2FPT0WU
TE-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfJT2NIUUN3ME2wMlExPTRizszN MYXTRW5ITVJ?
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHsd2VKSzVyPUCuNVExOjhizszN NV7GdZZCW0GQR1XS
SW962 NW[2U29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\YcmhuUUN3ME2wMlEyOjl{IN88US=> M{\RN3NCVkeHUh?=
KLE MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILlbYxKSzVyPUCuNVE{OTdizszN NXKwXlFGW0GQR1XS
MC116 M3v6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnxOJVIUUN3ME2wMlEyPDFizszN M4LrSXNCVkeHUh?=
NMC-G1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXyTlVKSzVyPUCuNVE3ODZizszN M4\MfnNCVkeHUh?=
KU812 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHwTWM2OD1yLkGxPFg{KM7:TR?= M{PoU3NCVkeHUh?=
COLO-829 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTnell5UUN3ME2wMlEzOjF|IN88US=> NVmySWRKW0GQR1XS
NTERA-S-cl-D1 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX0d4JRUUN3ME2wMlEzOjh|IN88US=> MWXTRW5ITVJ?
IST-MEL1 M3Xwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWyTWM2OD1yLkGzOFUh|ryP MWHTRW5ITVJ?
MLMA MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3qTWM2OD1yLkG0NFMzKM7:TR?= MlfOV2FPT0WU
LS-123 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\XZ2lEPTB;MD6xOFA3PCEQvF2= NX7rVJpCW0GQR1XS
LB2518-MEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m1V2lEPTB;MD6xOFE3OiEQvF2= NVrlNVVkW0GQR1XS
NB69 M{nkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHiTWM2OD1yLkG0OFM3KM7:TR?= NXLz[IdxW0GQR1XS
8-MG-BA M{P0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;XUnlKSzVyPUCuNVU1PThizszN NF\vTVNUSU6JRWK=
K5 M13WOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQN|IzUUN3ME2wMlE3PDh7IN88US=> MYfTRW5ITVJ?
KINGS-1 NUXZO3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i3cmlEPTB;MD6xOlY3PiEQvF2= NVO4PYVbW0GQR1XS
SF268 M1rFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6[2JMUUN3ME2wMlE4PDB2IN88US=> Ml7wV2FPT0WU
PF-382 M2\jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOxd4d1UUN3ME2wMlE4Pjd6IN88US=> M3viOHNCVkeHUh?=
SH-4 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4faXWlEPTB;MD6xPFQyOyEQvF2= NEX2UZVUSU6JRWK=
NALM-6 M1m1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHlRpdnUUN3ME2wMlE6Ojl3IN88US=> MUjTRW5ITVJ?
CP66-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\wXoF7UUN3ME2wMlE6PTNzIN88US=> NILUSmlUSU6JRWK=
697 NX32UW9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\GTWM2OD1yLkG5PVg4KM7:TR?= MnnKV2FPT0WU
CP67-MEL NGHGSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMkC0PFgh|ryP MYXTRW5ITVJ?
DSH1 NWXmTGxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTVTWM2OD1yLkK0NFAyKM7:TR?= MnLRV2FPT0WU
HCE-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P2SGlEPTB;MD6yOlQ{QSEQvF2= NX;OSI57W0GQR1XS
MZ2-MEL M1PvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMki1N|ch|ryP NYL2e|lrW0GQR1XS
BL-41 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HB[2lEPTB;MD6yPVEzOyEQvF2= MVLTRW5ITVJ?
HUTU-80 NXfIZYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwM{G0NkDPxE1? M2ixcHNCVkeHUh?=
LOXIMVI M{H1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;U[4VKSzVyPUCuN|E2ODNizszN MWLTRW5ITVJ?
no-10 NXLhPXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwM{G5N|Eh|ryP M3fvc3NCVkeHUh?=
KARPAS-422 NV:3UlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7BR|NnUUN3ME2wMlM{QTl5IN88US=> NWjUe25rW0GQR1XS
SW684 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLPXHd{UUN3ME2wMlM1QThizszN NHP1foxUSU6JRWK=
SF126 M2HtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{W0NUDPxE1? NWrXPYdZW0GQR1XS
D-263MG M2LabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nCW2lEPTB;MD6zOlIzPCEQvF2= M2XiZ3NCVkeHUh?=
OVCAR-4 M4rBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDZTWM2OD1yLkO3OFM{KM7:TR?= MYnTRW5ITVJ?
BB49-HNC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn0O3NDUUN3ME2wMlM5PTl7IN88US=> NVS3NGxRW0GQR1XS
ONS-76 NG[1cFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\CVJloUUN3ME2wMlQzQTVzIN88US=> NYHw[HhsW0GQR1XS
MZ7-mel Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GzOWlEPTB;MD60O|kyOSEQvF2= MVLTRW5ITVJ?
RCC10RGB NVTPPWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TLdGlEPTB;MD60PVEyKM7:TR?= M3HUSHNCVkeHUh?=
BOKU NEjUNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\SbmE5UUN3ME2wMlQ6OTN|IN88US=> M4HSV3NCVkeHUh?=
no-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwNUCyNlgh|ryP MmXiV2FPT0WU
IST-SL2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX64W5cxUUN3ME2wMlUxOzB{IN88US=> MUXTRW5ITVJ?
RKO Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1VYY6UUN3ME2wMlUzQTZ4IN88US=> Ml7oV2FPT0WU
HT-144 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD1yLkWzOlA6KM7:TR?= M3THPXNCVkeHUh?=
NCI-H446 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHmZVNKSzVyPUCuOlI4PiEQvF2= MWTTRW5ITVJ?
QIMR-WIL M{TaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36zemlEPTB;MD63NFYzQSEQvF2= NX\zTVZiW0GQR1XS
MHH-PREB-1 NEmxZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nJ[mlEPTB;MD63OFQ3QSEQvF2= M2GyWHNCVkeHUh?=
EW-16 M17sOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jJWGlEPTB;MD63OlE4QCEQvF2= NEH5bJdUSU6JRWK=
EW-24 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle1TWM2OD1yLke4NVY2KM7:TR?= MoTBV2FPT0WU
LB373-MEL-D NVLNOlFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXPTWM2OD1yLkiyOVA5KM7:TR?= MWTTRW5ITVJ?
TE-9 NUW3XoZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;sZXpvUUN3ME2wMlg4PTN{IN88US=> MWHTRW5ITVJ?
A3-KAW NGPGbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3FdFZKSzVyPUCuPVg1PTJizszN MXnTRW5ITVJ?
A101D M1vvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f1dmlEPTB;MT6wN|A1OyEQvF2= MoXXV2FPT0WU
OCUB-M M4nRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLiTWM2OD1zLkC0OFEzKM7:TR?= MVXTRW5ITVJ?
ES4 NETtdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvEWmY6UUN3ME2xMlA2OTR3IN88US=> NVn4c|Q1W0GQR1XS
TE-6 NX:xSVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQ[oJKSzVyPUGuNlEzOjZizszN Mk\NV2FPT0WU
D-502MG M1qzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorpTWM2OD1zLkKzN|c3KM7:TR?= MVHTRW5ITVJ?
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD1zLkK0OFEzKM7:TR?= NHnyUXZUSU6JRWK=
SNU-C2B NYTqUmpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwM{C1PFkh|ryP NHT0N3ZUSU6JRWK=
NCI-H1838 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rUTmlEPTB;MT6zNFc{OyEQvF2= NXPmSGxnW0GQR1XS
NKM-1 NYrZe4JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HnOWlEPTB;MT6zNFg2QSEQvF2= M1PPVHNCVkeHUh?=
GI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD1zLkO2NlIh|ryP M{f1Z3NCVkeHUh?=
NB5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwM{m4Nlch|ryP NGrmVmFUSU6JRWK=
CAS-1 NFTQSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTrSXJKSzVyPUGuOFA6QTJizszN M{SwSnNCVkeHUh?=
HCE-T NVOzWJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7GOJBKSzVyPUGuOVY4OTRizszN NInpbVRUSU6JRWK=
SBC-1 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm5TWM2OD1zLkW3PVg1KM7:TR?= NUfkUmR6W0GQR1XS
JiyoyeP-2003 NUjjcIFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYfWlEPTB;MT63N|Q3PiEQvF2= MWXTRW5ITVJ?
TE-5 NVXaN|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T6TWlEPTB;MT63PVE{QSEQvF2= M1G2XnNCVkeHUh?=
CAN M2DlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jYN2lEPTB;MT64NlI2OiEQvF2= M4SzXHNCVkeHUh?=
SK-UT-1 M2fNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHyWFNLUUN3ME2yMlE3Pjl|IN88US=> NV7HbpI4W0GQR1XS
JVM-2 NGTSbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXpO5lKSzVyPUKuN|YzQDRizszN NUi3fYRTW0GQR1XS
LB771-HNC NIT5cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrHTWM2OD1{LkW3OVUyKM7:TR?= M3O2bXNCVkeHUh?=
NCCIT NETORVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwNY1KSzVyPUKuPFY3OTZizszN MY\TRW5ITVJ?
NCI-H2126 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH0TWM2OD1{Lki3OVUzKM7:TR?= NIq5bHVUSU6JRWK=
Calu-6 NXi2Slg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITINGFKSzVyPUOuNFU4PDFizszN M4H1bHNCVkeHUh?=
SK-LMS-1 M3XqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV25Zo5HUUN3ME2zMlEyQDh4IN88US=> M4[3bHNCVkeHUh?=
ARH-77 M1r1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwNE[5NVUh|ryP MlHWV2FPT0WU
NB17 NXHDS282T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNwNkO4OFch|ryP M2rrZXNCVkeHUh?=
A253 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwN{OyOFYh|ryP NVX6VWhxW0GQR1XS
OPM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLcmQxUUN3ME20MlI4Pjh3IN88US=> NHPjcWlUSU6JRWK=
MV-4-11 NUfFZmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjTWM2OD12LkO2OFU1KM7:TR?= NIrvWnZUSU6JRWK=
SR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz2[FVKSzVyPUSuOFk6PTRizszN MlPRV2FPT0WU
KG-1 NHu3SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7DU2pKSzVyPUSuOlA5PDVizszN NUPEcXhZW0GQR1XS
OCI-AML2 NEXTV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki2TWM2OD13Lki2NVU1KM7:TR?= Mmn4V2FPT0WU
D-247MG NVzC[plXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnzPHpKSzVyPU[uNVI2OTlizszN M3\0cHNCVkeHUh?=
DJM-1 NH;ncZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwNEi1OVgh|ryP MULTRW5ITVJ?
RPMI-6666 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdwMkewOlch|ryP MVvTRW5ITVJ?
KARPAS-45 NETJXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GWY1GUUN3ME23MlUyPjdzIN88US=> NGHrcWZUSU6JRWK=
LP-1 M2i0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ucmV{UUN3ME23MlU1Pzh{IN88US=> M3LGVXNCVkeHUh?=
RS4-11 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTdwNkW3PFch|ryP M2PlTHNCVkeHUh?=
DU-4475 M1e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Cz[mlEPTB;OD6yNVY2OiEQvF2= MnLKV2FPT0WU
MONO-MAC-6 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j0PWlEPTB;OD6yO|A3PiEQvF2= MWnTRW5ITVJ?
NCI-SNU-16 NXWyPWRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwNU[xNlgh|ryP M2LiR3NCVkeHUh?=
SJSA-1 NIfZUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnITWM2OD16LkeyPFA2KM7:TR?= M4TtenNCVkeHUh?=
MMAC-SF NIm5[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;4ZVl1UUN3ME24Mlc6OzB5IN88US=> MX\TRW5ITVJ?
SK-NEP-1 M1XzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXtO21vUUN3ME24Mlg6OTV3IN88US=> MkXvV2FPT0WU
J-RT3-T3-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKyfVVCUUN3ME24Mlk3PTJ7IN88US=> NGK0XYZUSU6JRWK=
SKM-1 NULie|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTlwMEG3N|Qh|ryP M1\xfnNCVkeHUh?=
LB2241-RCC Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L6R2lEPTB;OT6wNlAyOiEQvF2= NV7QdXE1W0GQR1XS
SIG-M5 NFTDOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRXGlEPTB;OT6wNlQ6OyEQvF2= M1KzSXNCVkeHUh?=
EVSA-T NXTO[VJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaZ4ZLUUN3ME25MlI4Pzl|IN88US=> MYHTRW5ITVJ?
GT3TKB MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfr[3dJUUN3ME25MlM2PTR4IN88US=> M1nQfHNCVkeHUh?=
NB6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnexTWM2OD17LkmyNlU6KM7:TR?= M2\DSXNCVkeHUh?=
EHEB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFyLkC2OVYh|ryP NYK0dGs3W0GQR1XS
HEL NUGyXW5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLQTWM2OD1zMD60O|c3KM7:TR?= NEW3U4NUSU6JRWK=
ALL-PO MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\Y[WlEPTB;MUCuO|k{QCEQvF2= MnT1V2FPT0WU
TGW NILGcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHre29DUUN3ME2xNU4zQDJ6IN88US=> MkmyV2FPT0WU
BC-3 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr0cYpKSzVyPUGyMlEyOzhizszN M4PZNXNCVkeHUh?=
IA-LM MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3re|JIUUN3ME2xNk41PDR3IN88US=> NH7PVnBUSU6JRWK=
UACC-257 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPIN3J2UUN3ME2xNk46OTl6IN88US=> MojxV2FPT0WU
KP-N-YS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O2[mlEPTB;MUKuPVI5OyEQvF2= MYLTRW5ITVJ?
Raji M3jzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXGe4ZKSzVyPUGzMlc1QTdizszN MmqyV2FPT0WU
SF539 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf5TWM2OD1zMz64OVU4KM7:TR?= M2L2eHNCVkeHUh?=
DMS-153 M{fjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF2LkCwNlgh|ryP M3\GVnNCVkeHUh?=
L-540 NH7Ve5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnhUFRKSzVyPUG1MlA3PzJizszN MUPTRW5ITVJ?
MN-60 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P0b2lEPTB;MUWuNVk4QSEQvF2= MoD0V2FPT0WU
RPMI-8866 NVXMdJZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v3bGlEPTB;MUeuOFQ2PCEQvF2= M1r1OHNCVkeHUh?=
NCI-H510A MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLzTWM2OD1zOT6zPVc{KM7:TR?= NHvFT3lUSU6JRWK=
NB13 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCyNphZUUN3ME2xPU41QDd5IN88US=> M1Puc3NCVkeHUh?=
HAL-01 NFPZWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPqTWM2OD1zOT63OVQ{KM7:TR?= NWPy[lgzW0GQR1XS
NCI-H720 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJyLkK3N|Mh|ryP NYLPS|dyW0GQR1XS
REH MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnLTWM2OD1{MD62N|U4KM7:TR?= Ml3tV2FPT0WU
KNS-81-FD MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf4UFdKSzVyPUKzMlE1PiEQvF2= MX;TRW5ITVJ?
HC-1 NXOwV2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1{ND61OVUyKM7:TR?= Mni1V2FPT0WU
NCI-H2141 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TDfWlEPTB;MkSuO|c2PCEQvF2= NETj[5JUSU6JRWK=
MOLT-4 NWK3WXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ4Lk[3OVMh|ryP MWjTRW5ITVJ?
OMC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonBTWM2OD1{Nz6xOFIzKM7:TR?= MVTTRW5ITVJ?
LC-1F NH3jS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nMXGlEPTB;MkeuN|I1PSEQvF2= NXO2e|R5W0GQR1XS
NCI-H1304 NFS2dJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKbVJKSzVyPUK4MlE3OjhizszN M4LsdXNCVkeHUh?=
BC-1 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ6Lk[1NUDPxE1? NEfLOWtUSU6JRWK=
NCI-H64 M{\vZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ7Lk[yOVMh|ryP Mn;ZV2FPT0WU
MOLT-16 M321bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjVU4lKSzVyPUK5MlYzQTJizszN M3y3[nNCVkeHUh?=
U-87-MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH6ZYxKSzVyPUOwMlc3PiEQvF2= M1uxRnNCVkeHUh?=
GAK M2S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf5[o9oUUN3ME2zNU4zPjh4IN88US=> M3KzU3NCVkeHUh?=
ES8 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPPTWM2OD1|Mj6xNlUzKM7:TR?= NGnV[lZUSU6JRWK=
HCC1599 NXjzfWIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN{LkOzNlUh|ryP M{LhW3NCVkeHUh?=
EB-3 NIXGUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLJTlJKUUN3ME2zOE4{OTF5IN88US=> M3vwcHNCVkeHUh?=
HCC1187 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHhTWM2OD1|NT64NFUzKM7:TR?= M4jy[nNCVkeHUh?=
SK-PN-DW M3\yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrHeJRHUUN3ME2zOk4yQTR|IN88US=> NYTV[|V4W0GQR1XS
JVM-3 NHz2PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTN5LkKzN|gh|ryP MkL2V2FPT0WU
HCC2157 NEXISG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTN5Lkm5OFYh|ryP NIDkfVBUSU6JRWK=
A4-Fuk NUDVTGM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTN6LkGwNFkh|ryP M4DD[nNCVkeHUh?=
COR-L279 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHHTWM2OD12MD6yPFUyKM7:TR?= MUnTRW5ITVJ?
DEL M1nwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjjTWM2OD12MT65NFg3KM7:TR?= MXXTRW5ITVJ?
NCI-H1395 NHzTcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR{LkCxOlMh|ryP MnjYV2FPT0WU
MHH-NB-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOwTWM2OD12Mz6wPFE5KM7:TR?= NHTYTGZUSU6JRWK=
NCI-H2107 NVfJbXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK2TXFKSzVyPUSzMlQ5PDZizszN MlvUV2FPT0WU
NEC8 M171Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7NTWM2OD12ND6zN|Yh|ryP NXiyZVc5W0GQR1XS
COLO-684 NGjlcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17BO2lEPTB;NE[uNlI2QCEQvF2= MljiV2FPT0WU
LS-411N NYfQUZU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T4OGlEPTB;NEiuOFc1QCEQvF2= MYjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID